Key facts
- PineTree Therapeutics’s last known valuation is $358.0M (Aug 2025).
- It has raised $97.5M.
- Notable investors include Korea Investment Partners, Smilegate Investment, InterVest, STIC Ventures, Schmidt (South Korea) — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for PineTree Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for PineTree Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PineTree Therapeutics
Developer of biological therapeutics technology designed to treat unmet needs in oncology and infectious diseases. The company utilizes tumor-associated essential receptor-targeting antibody and virus-targeting recombinant agent platforms for infectious disease technology, enabling medical professionals to develop an anticancer drug for solid cancer patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 35
- Website
- pinetreetx.com/
- Ownership
- Privately Held (backing)
PineTree Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PineTree Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PineTree Therapeutics in its N-PORT filings yet. We sweep new filings monthly.